New research has assessed a genetically engineered fungus for the control of malaria mosquitoes in the first semi-field trial, demonstrating that populations were reduced by more than 99%.
Browsing: Parasitic > Protozoan Infections
Argentina and Algeria have officially been certified as free of malaria by the WHO, both becoming the second country in their respective regions to achieve this certification.
A large-scale trial of RTS,S – the world’s first malaria vaccine to provide partial protection – is due to commence in Malawi, Kenya and Ghana.
A huge upsurge in malaria cases has been caused by Venezuela’s socioeconomic and political crisis, undoing years of progress and endangering neighbouring countries, according to research presented at ECCMID.
A single, oral dose of antimalarial DSM265 has cleared seven volunteers of a Plasmodium falciparum infection, according to the trial from the Medicines for Malaria Venture.
With progress plateauing for a second consecutive year and global financing also levelling off, the WHO has called for a ‘high burden to high impact’ country-led strategy.
Researchers from Imperial College London have reported their recent success in using ‘gene drive’ technology to block female mosquito reproduction, resulting in the total collapse of caged populations of Anopheles gambiae in as little as 7–11 generations.
Genomics is increasingly being adopted into both research and clinical settings. Here, we speak to Dyann Wirth about the use of genomics in the field of malaria, from what it can uncover about the parasite to the hurdles that need to be overcome moving towards elimination.
Cerebral malaria is the most severe neurological complication of Plasmodium falciparum infection. Here, the authors discuss how NRG-1 could attenuate brain injury and mortality.
The US FDA have approved Krintafel (tafenoquine) for the radical cure of Plasmodium vivax malaria infections, the first approval for such a drug in 50 years.